长春高新GS3-007a干混悬剂临床试验申请获受理

Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical, received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a, a drug aimed at treating idiopathic short stature (ISS) [1] Group 1 - Changchun Jinsai Pharmaceutical is responsible for the development of GS3-007a, which is an orally administered small molecule growth hormone secretagogue [1] - The drug is classified as a Class 1 chemical drug in the registration process [1] - The acceptance of the clinical trial application marks a significant step in the drug's development for treating ISS [1]